Goto Yoshiaki, Yamada So, Yamada Shoko M, Nakaguchi Hiroshi, Hoya Katsumi, Murakami Mineko, Yamazaki Kazuto, Ishida Yasuo, Matsuno Akira
Department of Neurosurgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara-City, Chiba 299-0111, Japan.
World J Surg Oncol. 2014 Apr 26;12:123. doi: 10.1186/1477-7819-12-123.
Combined chemotherapy and prophylactic cranial irradiation has improved the prognosis of children with acute leukemia. However cranial irradiation carries a latent risk of the induction of secondary intracranial tumors. We encountered a patient who developed multiple intracranial radiation-induced meningiomas (RIMs) 25 years after prophylactic cranial irradiation for the treatment of acute leukemia in childhood. The patient had 3 intracranial lesions, 1 of which showed rapid growth within 6 months; another of the tumors also enlarged within a short period. All of the tumors were surgically treated, and immunohistochemistry indicated a high MIB-1 labeling index in each of the multiple lesions. In the literature, the MIB-1 labeling indices of 27 tumors from 21 patients were examined. Among them, 12 recurrent tumors showed higher MIB-1 labeling indices compared to the MIB-1 labeling indices of the non-recurrent tumors. Overall, 11 of the patients with RIM had multiple lesions and 8 cases developed recurrence (72.7%). RIM cases with multiple lesions had higher MIB-1 labeling indices compared to the MIB-1 labeling indices of cases with single lesions. Collectively, these data showed that the MIB-1 labeling index is as important for predicting RIM recurrences, as it is for predicting sporadic meningioma (SM) recurrences. RIMs should be treated more aggressively than SMs because of their greater malignant potential.
联合化疗和预防性颅脑照射改善了急性白血病患儿的预后。然而,颅脑照射存在诱发继发性颅内肿瘤的潜在风险。我们遇到一名患者,其在儿童期因急性白血病接受预防性颅脑照射25年后发生了多发颅内放射诱发脑膜瘤(RIM)。该患者有3个颅内病灶,其中1个在6个月内迅速生长;另一个肿瘤也在短时间内增大。所有肿瘤均接受了手术治疗,免疫组化显示多个病灶中每个病灶的MIB-1标记指数都很高。在文献中,对21例患者的27个肿瘤的MIB-1标记指数进行了检查。其中,12个复发性肿瘤的MIB-1标记指数高于非复发性肿瘤的MIB-1标记指数。总体而言,11例RIM患者有多个病灶,8例发生复发(72.7%)。与单发病灶的病例相比,多发病灶的RIM病例的MIB-1标记指数更高。总的来说,这些数据表明,MIB-1标记指数在预测RIM复发方面与预测散发性脑膜瘤(SM)复发一样重要。由于RIM具有更大的恶性潜能,因此对其治疗应比SM更积极。